John Maraganore was the founding CEO and a director of Alnylam Pharmaceuticals - the leading RNAi therapeutics company - which he led for nearly 20 years from 2002-2021. At Alnylam, he led the company’s pioneering efforts to advance RNAi therapeutics as a whole new class of medicines. John built and led the company from early platform research on RNAi through global approval and commercialization of the first five RNAi medicines including ONPATTRO®, GIVLAARI®, OXLUMO®, LEQVIO® and AMVUTTRA®. He led the company’s value creation strategy, raising over $7.5B in capital, forming over 20 major pharmaceutical alliances, and creating over $25B in market capitalization.

Prior to Alnylam, John held senior leadership roles at Millennium Pharmaceuticals, Inc., and at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection, marketed by The Medicines Company. Prior to Biogen, John was a scientist at ZymoGenetics, Inc., and the Upjohn Company.

John is currently the CEO and principal of JMM Innovations, LLC, committed to the advancement of biomedical innovation to patients. In addition to his role at Magnetic Ventures, he is a Venture Partner with Arch Ventures, a Venture Advisor with Atlas Ventures, an Executive Advisor with Blackstone, a Senior Advisor with Jeffries, and an Executive Partner with RTW Investments, in addition to a number of undisclosed investment funds. He serves on the boards of Beam Therapeutics, Hemab Therapeutics, Kymera Therapeutics, Rapport Therapeutics and Takeda Pharmaceuticals. He also serves on a number of private company and non-profit boards, including City Therapeutics as an Executive Chair and Corsera Health as co-CEO. He also serves as a strategic advisor to a number of public and private biopharmaceutical companies. He is a member of the Biotechnology Innovation Organization board, where he was Chair from 2017-2019 and serves as Chair Emeritus.

John supports a number of academic research institutions and initiatives, including as a member of the Visiting Committee for the MIT Biology Department; Advisory Committee for the Innovative Genomics Institute at the University of California, Berkeley; and as Chair of the Therapeutics Discovery Institute at the University of Chicago. John and his wife Christine support the Maraganore Early Independence Fellowship at the UMass Chan Medical School.

John received his B.S., M.S,. and Ph.D. degrees in the biological sciences, biochemistry and molecular biology at the University of Chicago.